Research Tracker›Biomarker Atlas›Lyme Disease›Serum CXCL13 (PTLDS research)

Serum CXCL13 (PTLDS research) in Lyme Disease

Serum CXCL13 (PTLDS research), also described as B-cell chemokine, belongs to the chronic/ptlds group of Lyme Disease (Lyme borreliosis, Borrelia burgdorferi infection) markers, but reports against healthy controls, treated Lyme point in different directions. Symptom domains tied to this marker in the source include persistent symptoms research. The finding is drawn from Aucott et al. 2014; it describes group-level differences, not a threshold that classifies an individual.

↕ InconsistentChronic/PTLDS

Summary

Direction in Lyme Disease↕ Inconsistent — reported as both higher and lower across studies, with no consistent direction
CategoryChronic/PTLDS
Also described asB-cell chemokine
Compared againstHC, treated Lyme (healthy controls, treated Lyme)
Associated symptomsPersistent symptoms research
Test typeBlood test (serum / plasma / whole blood)
SourceAucott et al. 2014 — doi:10.1016/j.amjmed.2014.02.016
Condition atlasLyme Disease Biomarker Atlas

Related Chronic/PTLDS markers in Lyme Disease

Full list: Lyme Disease Biomarker Atlas.

Frequently asked questions

Is Serum CXCL13 (PTLDS research) high or low in Lyme Disease?

Mixed. Some studies report higher and others lower Serum CXCL13 (PTLDS research) in Lyme Disease compared with healthy controls, treated Lyme, so no single direction is established. Source: Aucott et al. 2014.

What symptoms is Serum CXCL13 (PTLDS research) associated with in Lyme Disease?

The cited literature associates this marker with Persistent symptoms research. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures Serum CXCL13 (PTLDS research)?

It is measured as a blood test (serum / plasma / whole blood). Many of the cited studies used research-grade assays, so clinical availability may vary.

Is one abnormal Serum CXCL13 (PTLDS research) result diagnostic of Lyme Disease?

No. No single biomarker is diagnostic of Lyme Disease. Serum CXCL13 (PTLDS research) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). Serum CXCL13 (PTLDS research) in Lyme Disease: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/lyme/serum-cxcl13-ptlds-research.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Page generated from lyme.json · Browse: Lyme Disease atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.